Hos tidligere ubehandlede patienter behandlet med ADVATE i et igangværende klinisk studie udviklede 5 (20%) af 25 patienter inhibitorer mod faktor VIII.
In previously untreated patients in an ongoing clinical study, 5 (20%) of 25 patients who received ADVATE developed inhibitors to factor VIII.